Literature DB >> 12207151

Survival of multiple sclerosis patients in the Belgrade population.

Tatjana Pekmezovic1, Mirjana Jarebinski, Jelena Drulovic, Nebojsa Stojsavljevic, Zvonimir Levic.   

Abstract

The aim of this study was to estimate survival rates of multiple sclerosis (MS) patients in the Belgrade population, Yugoslavia, and furthermore, to determine the prognostic value of some demographic and clinical variables for survival. The cumulative survival probability was calculated by the Kaplan-Meier method. The prognostic value of different variables was assessed by univariate and multivariate analyses using the Cox regression model. In the Belgrade population, the cumulative 25-year survival probability of MS patients and the mean survival time from MS onset were 73.2% and 38 years, respectively. The univariate analysis showed that survival was significantly related to sex, age at onset, course of disease and monoregional initial symptoms. A multivariate model demonstrated that a relapsing-remitting course of MS and monoregional onset were predictors of a better prognosis. The presence of motor symptoms at the onset was found to be an independent predictor of a poorer outcome of MS. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12207151     DOI: 10.1159/000065641

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  2 in total

Review 1.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

2.  Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Authors:  Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.